Trends in inpatient antiparkinson drug use in the USA, 2001-2012.
Identifieur interne : 000449 ( PubMed/Corpus ); précédent : 000448; suivant : 000450Trends in inpatient antiparkinson drug use in the USA, 2001-2012.
Auteurs : James A G. Crispo ; Yannick Fortin ; Dylan P. Thibault ; Matthew Emons ; Lise M. Bjerre ; Dafna E. Kohen ; Santiago Perez-Lloret ; Donald Mattison ; Allison W. Willis ; Daniel KrewskiSource :
- European journal of clinical pharmacology [ 1432-1041 ] ; 2015.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antiparkinson Agents (therapeutic use), Catechol O-Methyltransferase Inhibitors (therapeutic use), Cholinergic Antagonists (therapeutic use), Dopamine Agonists (therapeutic use), Drug Utilization (trends), Female, Humans, Inpatients (statistics & numerical data), Levodopa (therapeutic use), Male, Middle Aged, Monoamine Oxidase Inhibitors (therapeutic use), Parkinson Disease (drug therapy), Practice Patterns, Physicians' (trends), United States.
- MESH :
- chemical , therapeutic use : Antiparkinson Agents, Catechol O-Methyltransferase Inhibitors, Cholinergic Antagonists, Dopamine Agonists, Levodopa, Monoamine Oxidase Inhibitors.
- geographic : United States.
- drug therapy : Parkinson Disease.
- statistics & numerical data : Inpatients.
- trends : Drug Utilization, Practice Patterns, Physicians'.
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged.
Abstract
Although therapeutic options and clinical guidelines for Parkinson's disease (PD) have changed significantly in the past 15 years, prescribing trends in the USA remain unknown. The purpose of this population-based cohort study was to examine patterns of inpatient antiparkinson drug use between January 2001 and December 2012 in relation to clinical guideline publication, drug introduction/withdrawal, and emerging safety concerns.
DOI: 10.1007/s00228-015-1881-4
PubMed: 26081062
Links to Exploration step
pubmed:26081062Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Trends in inpatient antiparkinson drug use in the USA, 2001-2012.</title><author><name sortKey="Crispo, James A G" sort="Crispo, James A G" uniqKey="Crispo J" first="James A G" last="Crispo">James A G. Crispo</name><affiliation><nlm:affiliation>McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON, Canada, jcris021@uottawa.ca.</nlm:affiliation></affiliation></author><author><name sortKey="Fortin, Yannick" sort="Fortin, Yannick" uniqKey="Fortin Y" first="Yannick" last="Fortin">Yannick Fortin</name></author><author><name sortKey="Thibault, Dylan P" sort="Thibault, Dylan P" uniqKey="Thibault D" first="Dylan P" last="Thibault">Dylan P. Thibault</name></author><author><name sortKey="Emons, Matthew" sort="Emons, Matthew" uniqKey="Emons M" first="Matthew" last="Emons">Matthew Emons</name></author><author><name sortKey="Bjerre, Lise M" sort="Bjerre, Lise M" uniqKey="Bjerre L" first="Lise M" last="Bjerre">Lise M. Bjerre</name></author><author><name sortKey="Kohen, Dafna E" sort="Kohen, Dafna E" uniqKey="Kohen D" first="Dafna E" last="Kohen">Dafna E. Kohen</name></author><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name></author><author><name sortKey="Mattison, Donald" sort="Mattison, Donald" uniqKey="Mattison D" first="Donald" last="Mattison">Donald Mattison</name></author><author><name sortKey="Willis, Allison W" sort="Willis, Allison W" uniqKey="Willis A" first="Allison W" last="Willis">Allison W. Willis</name></author><author><name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26081062</idno><idno type="pmid">26081062</idno><idno type="doi">10.1007/s00228-015-1881-4</idno><idno type="wicri:Area/PubMed/Corpus">000449</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000449</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Trends in inpatient antiparkinson drug use in the USA, 2001-2012.</title><author><name sortKey="Crispo, James A G" sort="Crispo, James A G" uniqKey="Crispo J" first="James A G" last="Crispo">James A G. Crispo</name><affiliation><nlm:affiliation>McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON, Canada, jcris021@uottawa.ca.</nlm:affiliation></affiliation></author><author><name sortKey="Fortin, Yannick" sort="Fortin, Yannick" uniqKey="Fortin Y" first="Yannick" last="Fortin">Yannick Fortin</name></author><author><name sortKey="Thibault, Dylan P" sort="Thibault, Dylan P" uniqKey="Thibault D" first="Dylan P" last="Thibault">Dylan P. Thibault</name></author><author><name sortKey="Emons, Matthew" sort="Emons, Matthew" uniqKey="Emons M" first="Matthew" last="Emons">Matthew Emons</name></author><author><name sortKey="Bjerre, Lise M" sort="Bjerre, Lise M" uniqKey="Bjerre L" first="Lise M" last="Bjerre">Lise M. Bjerre</name></author><author><name sortKey="Kohen, Dafna E" sort="Kohen, Dafna E" uniqKey="Kohen D" first="Dafna E" last="Kohen">Dafna E. Kohen</name></author><author><name sortKey="Perez Lloret, Santiago" sort="Perez Lloret, Santiago" uniqKey="Perez Lloret S" first="Santiago" last="Perez-Lloret">Santiago Perez-Lloret</name></author><author><name sortKey="Mattison, Donald" sort="Mattison, Donald" uniqKey="Mattison D" first="Donald" last="Mattison">Donald Mattison</name></author><author><name sortKey="Willis, Allison W" sort="Willis, Allison W" uniqKey="Willis A" first="Allison W" last="Willis">Allison W. Willis</name></author><author><name sortKey="Krewski, Daniel" sort="Krewski, Daniel" uniqKey="Krewski D" first="Daniel" last="Krewski">Daniel Krewski</name></author></analytic><series><title level="j">European journal of clinical pharmacology</title><idno type="eISSN">1432-1041</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson Agents (therapeutic use)</term><term>Catechol O-Methyltransferase Inhibitors (therapeutic use)</term><term>Cholinergic Antagonists (therapeutic use)</term><term>Dopamine Agonists (therapeutic use)</term><term>Drug Utilization (trends)</term><term>Female</term><term>Humans</term><term>Inpatients (statistics & numerical data)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Monoamine Oxidase Inhibitors (therapeutic use)</term><term>Parkinson Disease (drug therapy)</term><term>Practice Patterns, Physicians' (trends)</term><term>United States</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Catechol O-Methyltransferase Inhibitors</term><term>Cholinergic Antagonists</term><term>Dopamine Agonists</term><term>Levodopa</term><term>Monoamine Oxidase Inhibitors</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>United States</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Inpatients</term></keywords><keywords scheme="MESH" qualifier="trends" xml:lang="en"><term>Drug Utilization</term><term>Practice Patterns, Physicians'</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Although therapeutic options and clinical guidelines for Parkinson's disease (PD) have changed significantly in the past 15 years, prescribing trends in the USA remain unknown. The purpose of this population-based cohort study was to examine patterns of inpatient antiparkinson drug use between January 2001 and December 2012 in relation to clinical guideline publication, drug introduction/withdrawal, and emerging safety concerns.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26081062</PMID><DateCreated><Year>2015</Year><Month>07</Month><Day>14</Day></DateCreated><DateCompleted><Year>2016</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1041</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>8</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>European journal of clinical pharmacology</Title><ISOAbbreviation>Eur. J. Clin. Pharmacol.</ISOAbbreviation></Journal><ArticleTitle>Trends in inpatient antiparkinson drug use in the USA, 2001-2012.</ArticleTitle><Pagination><MedlinePgn>1011-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00228-015-1881-4</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Although therapeutic options and clinical guidelines for Parkinson's disease (PD) have changed significantly in the past 15 years, prescribing trends in the USA remain unknown. The purpose of this population-based cohort study was to examine patterns of inpatient antiparkinson drug use between January 2001 and December 2012 in relation to clinical guideline publication, drug introduction/withdrawal, and emerging safety concerns.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 16,785 inpatients receiving pharmacological treatment for PD were identified in the Cerner Health Facts database. Our primary outcome was standardized (age, sex, race, and census region) annual prevalence of antiparkinson drug use. We also examined antiparkinson medication trends and polypharmacy by age and sex.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The most frequently prescribed antiparkinson drugs between 2001 and 2012 were levodopa (85%) and dopamine agonists (28%). Dopamine agonist use began declining in 2007, from 34 to 27% in 2012. The decline followed publication of the American Academy of Neurology's practice parameter refuting levodopa toxicity, pergolide withdrawal, and pramipexole label revisions. Despite safety concerns for cognitive impairment and falls, individuals ≥80 years of age demonstrated stable rates of dopamine agonist use from 2001 to 2012. Polypharmacy was most common in younger patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Dopamine agonist use declined from 2007 to 2012, suggesting that increased awareness of safety issues and practice guidelines influenced prescribing. These events appear to have minimally influenced treatment provided to older PD patients. Antiparkinson prescribing trends indicate that safety and best practice information may be communicated effectively.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crispo</LastName><ForeName>James A G</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, Ottawa, ON, Canada, jcris021@uottawa.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortin</LastName><ForeName>Yannick</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Thibault</LastName><ForeName>Dylan P</ForeName><Initials>DP</Initials></Author><Author ValidYN="Y"><LastName>Emons</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bjerre</LastName><ForeName>Lise M</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>Kohen</LastName><ForeName>Dafna E</ForeName><Initials>DE</Initials></Author><Author ValidYN="Y"><LastName>Perez-Lloret</LastName><ForeName>Santiago</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Mattison</LastName><ForeName>Donald</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Willis</LastName><ForeName>Allison W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Krewski</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 NS081087</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Clin Pharmacol</MedlineTA><NlmUniqueID>1256165</NlmUniqueID><ISSNLinking>0031-6970</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065098">Catechol O-Methyltransferase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018680">Cholinergic Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018491">Dopamine Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2014 Feb;20(2):237-8</RefSource><PMID Version="1">24269282</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Metabolism. 2005 May;54(5 Suppl 1):39-44</RefSource><PMID Version="1">15877312</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoepidemiol Drug Saf. 2002 Mar;11(2):149-57</RefSource><PMID Version="1">11998540</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2003 Apr;60(4):529-33</RefSource><PMID Version="1">12707066</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Oct;26 Suppl 3:S2-41</RefSource><PMID Version="1">22021173</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoepidemiol Drug Saf. 2012 Jan;21(1):34-41</RefSource><PMID Version="1">22109939</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2010 Jul;16(6):365-9</RefSource><PMID Version="1">20471298</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 2003 Apr;110(4):373-80</RefSource><PMID Version="1">12658365</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Neuropharmacol. 2000 Sep-Oct;23(5):252-61</RefSource><PMID Version="1">11154092</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurotherapeutics. 2008 Apr;5(2):164-80</RefSource><PMID Version="1">18394561</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2002 Jan 8;58(1):11-7</RefSource><PMID Version="1">11781398</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2014 May;20(5):488-92; discussion 488</RefSource><PMID Version="1">24582073</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2011 Aug 30;77(9):851-7</RefSource><PMID Version="1">21832214</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Am Med Dir Assoc. 2014 Feb;15(2):90-4</RefSource><PMID Version="1">24314699</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2006 Apr 11;66(7):976-82</RefSource><PMID Version="1">16606908</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neural Transm (Vienna). 2009 Feb;116(2):179-91</RefSource><PMID Version="1">19142570</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Expert Opin Drug Saf. 2014 Mar;13(3):351-60</RefSource><PMID Version="1">24547918</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drugs Aging. 2007;24(4):261-73</RefSource><PMID Version="1">17432922</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Res. 2012 Mar;65(3):358-64</RefSource><PMID Version="1">22123498</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2011 Oct;26 Suppl 3:S42-80</RefSource><PMID Version="1">22021174</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Parkinsons Dis. 2013;3(2):105-38</RefSource><PMID Version="1">23938342</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2011 Oct 11;77(15):1420-6</RefSource><PMID Version="1">21917769</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Neurol. 2007 Sep;6(9):826-9</RefSource><PMID Version="1">17706566</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroepidemiology. 2010;34(3):143-51</RefSource><PMID Version="1">20090375</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Epidemiol. 2003 Jun 1;157(11):1015-22</RefSource><PMID Version="1">12777365</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2012 Oct 23;79(17):1774-80</RefSource><PMID Version="1">23054239</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2008;23 Suppl 3:S515-20</RefSource><PMID Version="1">18781678</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuropsychiatr Dis Treat. 2008 Aug;4(4):743-57</RefSource><PMID Version="1">19043519</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2009 Aug;66(2):142-5</RefSource><PMID Version="1">19743462</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurodegener Dis. 2013;11(2):63-71</RefSource><PMID Version="1">23038208</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurologist. 2011 Nov;17(6 Suppl 1):S54-66</RefSource><PMID Version="1">22045327</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Can J Neurol Sci. 2008 May;35(2):173-8</RefSource><PMID Version="1">18574930</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mov Disord. 2010 Jun 15;25(8):1053-60</RefSource><PMID Version="1">20222132</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Ther. 2013 Oct;35(10):1513-1525.e1</RefSource><PMID Version="1">24139423</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014;9(6):e99021</RefSource><PMID Version="1">24906013</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoepidemiol Drug Saf. 2011 May;20(5):450-6</RefSource><PMID Version="1">21322083</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychiatr Danub. 2009 Mar;21(1):114-8</RefSource><PMID Version="1">19270634</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurology. 2014 Jan 14;82(2):163-71</RefSource><PMID Version="1">24336138</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA Intern Med. 2014 Dec;174(12):1930-3</RefSource><PMID Version="1">25329919</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Funct Neurol. 2013 Jan-Mar;28(1):13-7</RefSource><PMID Version="1">23731911</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Drugs Aging. 2013 Sep;30(9):739-45</RefSource><PMID Version="1">23881697</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Parkinsonism Relat Disord. 2008;14(5):420-5</RefSource><PMID Version="1">18316232</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065098" MajorTopicYN="N">Catechol O-Methyltransferase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018680" MajorTopicYN="N">Cholinergic Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018491" MajorTopicYN="N">Dopamine Agonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004363" MajorTopicYN="N">Drug Utilization</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007297" MajorTopicYN="N">Inpatients</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="N">Practice Patterns, Physicians'</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4500853</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>04</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>06</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26081062</ArticleId><ArticleId IdType="doi">10.1007/s00228-015-1881-4</ArticleId><ArticleId IdType="pmc">PMC4500853</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000449 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000449 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26081062
|texte= Trends in inpatient antiparkinson drug use in the USA, 2001-2012.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26081062" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |